{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:41:15Z","timestamp":1791996075843,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012734","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000}}],"reference-count":183,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012734.pub2","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T11:37:50Z","timestamp":1770118670000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aminoglycosides, vancomycin, and metronidazole for people with cirrhosis and hepatic encephalopathy"],"prefix":"10.1002","volume":"2026","author":[{"given":"Rebecca","family":"Jeyaraj","sequence":"additional","affiliation":[{"name":"UCL Institute for Liver & Digestive Health; Division of Medicine, Royal Free Campus, University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry D","family":"Zacharias","sequence":"additional","affiliation":[{"name":"UCL Institute for Liver & Digestive Health; Division of Medicine, Royal Free Campus, University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam","family":"Vadera","sequence":"additional","affiliation":[{"name":"UCL Institute for Liver & Digestive Health; Division of Medicine, Royal Free Campus, University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Yang","family":"Low","sequence":"additional","affiliation":[{"name":"UCL Institute for Liver & Digestive Health; Division of Medicine, Royal Free Campus, University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[{"name":"Gastro Unit, Medical Division; Copenhagen University Hospital Hvidovre; Hvidovre Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6134-1026","authenticated-orcid":false,"given":"Marsha Y","family":"Morgan","sequence":"additional","affiliation":[{"name":"UCL Institute for Liver & Digestive Health; Division of Medicine, Royal Free Campus, University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD012734.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1111\/j.1440-1746.2010.06318.x","article-title":"Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver","volume":"25","author":"Dhiman","year":"2010","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.05.042","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases","volume":"61","author":"American Association for the Study of Liver Diseases; European Association for the Study of the Liver","year":"2014","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"EASL Clinical Practice Guidelines on the management of hepatic encephalopathy","volume":"77","author":"European Association for the Study of the Liver","year":"2022","journal-title":"Journal of Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012734.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000051415","article-title":"Diagnosis of encephalopathy","volume":"59","author":"Weissenborn","year":"1998","journal-title":"Digestion"},{"issue":"8","key":"10.1002\/14651858.CD012734.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1007\/s10620-017-4630-y","article-title":"A new look at precipitants of overt hepatic encephalopathy in cirrhosis","volume":"62","author":"Pantham","year":"2017","journal-title":"Digestive Diseases and Sciences"},{"issue":"7","key":"10.1002\/14651858.CD012734.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1053\/j.gastro.2010.02.015","article-title":"Persistence of cognitive impairment after resolution of overt hepatic encephalopathy","volume":"138","author":"Bajaj","year":"2010","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012734.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1478-3231.2009.02030.x","article-title":"Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines","volume":"29","author":"Gu\u00e9rit","year":"2009","journal-title":"Liver International"},{"issue":"42","key":"10.1002\/14651858.CD012734.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"15756","DOI":"10.3748\/wjg.v20.i42.15756","article-title":"Covert hepatic encephalopathy: agreement and predictive validity of different indices","volume":"20","author":"Montagnese","year":"2014","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/apt.13830","article-title":"Stepwise diagnosis in covert hepatic encephalopathy \u2013 critical flicker frequency and MELD-score as a first-step approach. Replication and pitfalls","volume":"45","author":"Zacharias","year":"2017","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"3-4","key":"10.1002\/14651858.CD012734.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/B:MEBR.0000043977.11113.2a","article-title":"Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach","volume":"19","author":"Montagnese","year":"2004","journal-title":"Metabolic Brain Disease"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD012734.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","article-title":"Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial","volume":"72","author":"Conn","year":"1977","journal-title":"Gastroenterology"},{"issue":"7872","key":"10.1002\/14651858.CD012734.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(74)91639-0","article-title":"Assessment of coma and impaired consciousness. A practical scale","volume":"304","author":"Teasdale","year":"1974","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012734.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1023\/A:1020645110880","article-title":"Neuropsychological aspects of portal-systemic encephalopathy","volume":"13","author":"Schomerus","year":"1998","journal-title":"Metabolic Brain Disease"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0168-8278(01)00026-5","article-title":"Neuropsychological characterization of hepatic encephalopathy","volume":"34","author":"Weissenborn","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1440-1746.1995.tb01041.x","article-title":"Figure connection test: a universal test for assessment of mental state","volume":"10","author":"Dhiman","year":"1995","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5114\/ceh.2019.95105","article-title":"Animal Naming Test - a simple and accurate test for diagnosis of minimal hepatic encephalopathy and prediction of overt hepatic encephalopathy","volume":"6","author":"Agarwal","year":"2020","journal-title":"Clinical and Experimental Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.29146","article-title":"The animal naming test: an easy tool for the assessment of hepatic encephalopathy","volume":"66","author":"Campagna","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1038\/s41598-024-54951-8","article-title":"Animal naming test stratifies the risk of falls and fall-related fractures in patients with cirrhosis","volume":"14","author":"Miwa","year":"2024","journal-title":"Scientific Reports"},{"issue":"7001","key":"10.1002\/14651858.CD012734.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(57)90005-3","article-title":"The electroencephalograph in liver disease","volume":"270","author":"Parsons-Smith","year":"1957","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1002\/14651858.CD012734.pub2-BIB0022|cit22","first-page":"S288","article-title":"Evoked potentials in liver diseases","volume":"12","author":"Chu","year":"1977","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1053\/jhep.2002.30957","article-title":"Critical flicker frequency for quantification of low-grade hepatic encephalopathy","volume":"35","author":"Kircheis","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1053\/j.gastro.2008.07.021","article-title":"Inhibitory control test for the diagnosis of minimal hepatic encephalopathy","volume":"135","author":"Bajaj","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ajg.2015.377","article-title":"Diagnosis of minimal hepatic encephalopathy using Stroop EncephalApp: a multicentre US-based, norm-based study","volume":"111","author":"Allampati","year":"2016","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0026|cit26","first-page":"784","article-title":"Lactulose in the treatment of chronic portalsystemic encephalopathy: a prospective double-blind, cooperative comparison of lactulose with neomycin","volume":"67","author":"Conn","year":"1974","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD012734.pub2-BIB0027|cit27","first-page":"2058","article-title":"Dilemmas of clinical experimentation: use of lactulose in portocaval encephalopathy","volume":"103","author":"Conn","year":"1974","journal-title":"Union Medicale du Canada"},{"issue":"9","key":"10.1002\/14651858.CD012734.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrgastro.2013.99","article-title":"The liver-brain axis in liver failure: neuroinflammation and encephalopathy","volume":"10","author":"Butterworth","year":"2013","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/9781119237662.ch10","volume-title":"Sherlock's Diseases of the Liver and Biliary System","author":"Morgan","year":"2018"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.abb.2013.03.016","article-title":"Inflammation and hepatic encephalopathy","volume":"536","author":"Coltart","year":"2013","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jceh.2018.04.007","article-title":"Hepatic encephalopathy and sarcopenia: two faces of the same metabolic alteration","volume":"9","author":"Lattanzi","year":"2019","journal-title":"Journal of Clinical and Experimental Hepatology"},{"issue":"11","key":"10.1002\/14651858.CD012734.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41579-023-00904-3","article-title":"The gut\u2013liver axis and gut microbiota in health and liver disease","volume":"21","author":"Hsu","year":"2023","journal-title":"Nature Reviews Microbiology"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"356\u201368","DOI":"10.1055\/a-2378-8942","article-title":"The value of ammonia as a biomarker in patients with cirrhosis","volume":"44","author":"Ballester","year":"2024","journal-title":"Seminars in Liver Disease"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/j.clinthera.2022.01.008","article-title":"Serum ammonia in cirrhosis: clinical impact of hyperammonemia, utility of testing, and national testing trends","volume":"44","author":"Deutsch-Link","year":"2022","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.14309\/ajg.0000000000000384","article-title":"Variability and lability of ammonia levels in healthy volunteers and patients with cirrhosis: implications for trial design and clinical practice","volume":"115","author":"Bajaj","year":"2020","journal-title":"American Journal of Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012734.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/s0168-8278(02)00436-1","article-title":"Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy","volume":"38","author":"Nicolao","year":"2003","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/s0002-9343(02)01477-8","article-title":"Correlation between ammonia levels and the severity of hepatic encephalopathy","volume":"114","author":"Ong","year":"2003","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012734.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jhep.2023.05.022","article-title":"Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis","volume":"79","author":"Ballester","year":"2023","journal-title":"Journal of Hepatology"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MCG.0000000000000443","article-title":"Serum ammonia is associated with transplant-free survival in hospitalized patients with acutely decompensated cirrhosis","volume":"50","author":"Patwardhan","year":"2016","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/hep.30534","article-title":"Prognostic role of ammonia in patients with cirrhosis","volume":"70","author":"Shalimar","year":"2019","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/gastro\/gow010","article-title":"Ammonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis","volume":"5","author":"Ravi","year":"2017","journal-title":"Gastroenterology Reports"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0042|cit42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003044.pub4","article-title":"Non-absorbable disaccharides versus placebo\/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis","author":"Gluud","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/hep.28598","article-title":"Nonabsorbable disaccharides for hepatic encephalopathy: a systematic review and meta-analysis","volume":"64","author":"Gluud","year":"2016","journal-title":"Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD012734.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011585.pub2","article-title":"Rifaximin for people with hepatic encephalopathy","author":"Zacharias","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.mayocp.2013.11.009","article-title":"Management of hepatic encephalopathy in the hospital","volume":"89","author":"Leise","year":"2014","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s44355-024-00011-x","article-title":"Gut microbiota and dynamics of ammonia metabolism in liver disease","volume":"1","author":"Jakhar","year":"2024","journal-title":"npj Gut and Liver"},{"issue":"10","key":"10.1002\/14651858.CD012734.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1111\/j.1572-0241.2001.04668.x","article-title":"Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis","volume":"96","author":"Bauer","year":"2001","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD012734.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1572-0241.2003.07475.x","article-title":"Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension","volume":"98","author":"Gunnarsdottir","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD012734.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1365-2036.2009.03994.x","article-title":"Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease","volume":"29","author":"Pande","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD012734.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/00365529850171549","article-title":"Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests","volume":"33","author":"Yang","year":"1998","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-4615-1989-8_13","article-title":"Neomycin reduces the intestinal production of ammonia from glutamine","volume":"368","author":"Hawkins","year":"1994","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1021\/cr0301088","article-title":"Molecular insights into aminoglycoside action and resistance","volume":"105","author":"Magnet","year":"2005","journal-title":"Chemical Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11011-013-9383-5","article-title":"Antibiotics for the treatment of hepatic encephalopathy","volume":"28","author":"Patidar","year":"2014","journal-title":"Metabolic Brain Disease"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jhep.2010.05.002","article-title":"Rifaximin in hepatic encephalopathy: more than just a non-absorbable antibiotic?","volume":"53","author":"Jalan","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/microorganisms11010024","article-title":"Vancomycin resistance in Enterococcus and Staphylococcus aureus","volume":"11","author":"Li","year":"2022","journal-title":"Microorganisms"},{"issue":"7","key":"10.1002\/14651858.CD012734.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2011.04590.x","article-title":"Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement","volume":"33","author":"Bajaj","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"6260","key":"10.1002\/14651858.CD012734.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bmj.282.6260.263","article-title":"A 20-year prospective study of cirrhosis","volume":"282","author":"Saunders","year":"1981","journal-title":"British Medical Journal (Clinical Research Ed.)"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01320309","article-title":"Survival and prognostic indicators in compensated and decompensated cirrhosis","volume":"31","author":"D'Amico","year":"1986","journal-title":"Digestive Diseases and Sciences"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(92)91188-A","article-title":"Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver","volume":"103","author":"De Jongh","year":"1992","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD012734.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1478-3231.2012.02830.x","article-title":"Prognostic indicators of survival in patients with compensated and decompensated cirrhosis","volume":"32","author":"Zipprich","year":"2012","journal-title":"Liver International"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1046\/j.1440-1746.2001.02487.x.","article-title":"Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis","volume":"16","author":"Das","year":"2001","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"8","key":"10.1002\/14651858.CD012734.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/j.1572-0241.2000.02265.x","article-title":"The prognostic significance of subclinical hepatic encephalopathy","volume":"95","author":"Hartmann","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD012734.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/ajg.2014.264","article-title":"Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization","volume":"109","author":"Patidar","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"Jepsen","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11011-011-9242-1","article-title":"Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease","volume":"26","author":"Lauridsen","year":"2011","journal-title":"Metabolic Brain Disease"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MEG.0b013e3283341b7d","article-title":"Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy","volume":"22","author":"Sharma","year":"2010","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0168-8278(01)00129-5","article-title":"Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients","volume":"35","author":"Amodio","year":"2001","journal-title":"Journal of Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD012734.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/ajg.2011.157","article-title":"The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers","volume":"106","author":"Bajaj","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2009.08.003","article-title":"Hepatic encephalopathy and fitness to drive","volume":"137","author":"Kircheis","year":"2009","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD012734.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/BF01367675","article-title":"Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive","volume":"26","author":"Schomerus","year":"1981","journal-title":"Digestive Diseases and Sciences"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/hep.510280108","article-title":"Subclinical hepatic encephalopathy impairs daily functioning","volume":"28","author":"Groeneweg","year":"1998","journal-title":"Hepatology"},{"issue":"9","key":"10.1002\/14651858.CD012734.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1478-3231.2009.02089.x","article-title":"Nighttime sleep disturbance does not correlate with neuropsychiatric impairment in patients with cirrhosis","volume":"29","author":"Montagnese","year":"2009","journal-title":"Liver International"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/ajg.2010.413","article-title":"Minimal hepatic encephalopathy is associated with falls","volume":"106","author":"Rom\u00e1n","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/lt.21593","article-title":"Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation","volume":"15","author":"Sotil","year":"2009","journal-title":"Liver Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD012734.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/lt.24153","article-title":"The impact of pretransplant hepatic encephalopathy on survival following liver transplantation","volume":"21","author":"Wong","year":"2015","journal-title":"Liver Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis","volume":"30","author":"Bustamante","year":"1999","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD012734.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/lt.21129","article-title":"Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease","volume":"13","author":"Stewart","year":"2007","journal-title":"Liver Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hep.24616","article-title":"Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study","volume":"55","author":"Rakoski","year":"2012","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012734.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"Review article: the burden of hepatic encephalopathy","volume":"25","author":"Poordad","year":"2007","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD012734.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.cgh.2012.05.016","article-title":"In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0082|cit82","doi-asserted-by":"crossref","unstructured":"Alaasar A Monis A Riad G Talkhan M Comparison of safety and efficacy of neomycin versus rifaximin in chronic recurrent hepatic encephalopathy QJM: an international journal of medicine 2024 117 Suppl 2 ii156","DOI":"10.1093\/qjmed\/hcae175.363"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0083|cit83","first-page":"284","article-title":"Individual comparison of three antiammonia therapies for treatment of hepatic encephalopathy","volume":"32","author":"D\u00e1vila-Sosa","year":"2016","journal-title":"Medicina Interna de M\u00e9xico"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0084|cit84","unstructured":"D\u00e1vila-Sosa D Individual comparison of three antiamonio therapies for treatment of hepatic encephalopathy [personal communication] Correspondence with authors"},{"issue":"11","key":"10.1002\/14651858.CD012734.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.13040\/IJPSR.0975-8232.6(11).4657-67","article-title":"The clinical effects of nitazoxanide in hepatic encephalopathy patients: a pilot study","volume":"6","author":"Elrakaybi","year":"2015","journal-title":"International Journal of Pharmaceutical Sciences and Research"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0086|cit86","unstructured":"Latif S Rashid Siraj M Khan FS Sarwar S Role of oral antibiotics \"neomycin vs ciprofloxacin\" for secondary prophylaxis of porto-systemic encephalopathy in liver cirrhotic patients Pakistan Journal of Medical and Health Sciences 2016 10 1 32 6"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0087|cit87","unstructured":"Latif S Role of oral antibiotics \"neomycin vs ciprofloxacin\" for secondary prophylaxis of porto-systemic encephalopathy in liver cirrhotic patients [personal communication] Correspondence with authors 2019"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ajg.2018.06.001","article-title":"Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: an open labeled randomized clinical trial","volume":"19","author":"Mekky","year":"2018","journal-title":"Arab Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-230X-13-13","article-title":"Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study","volume":"13","author":"Romeiro","year":"2013","journal-title":"BMC Gastroenterology"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0090|cit90","unstructured":"Romeiro F Erythromycin used as treatment for hepatic encephalopathy in patients with cirrhosis: a prospective, randomized, double-blind, controlled study Thesis 2011 1 83"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0091|cit91","unstructured":"Romeiro FG Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: a randomized double-blind study [personal communication] Correspondence with authors 2019"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0092|cit92","unstructured":"A prospective single centre open label trial of RBX2660 (microbiota suspension) in the management of hepatic encephalopathy https:\/\/clinicaltrials.gov\/study\/NCT03439982"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0093|cit93","unstructured":"Efficacy and safety of nitazoxanide in preventing recurrence of hepatic encephalopathy https:\/\/clinicaltrial.be\/en\/details\/60131"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0094|cit94","unstructured":"Efficacy and safety of nifuroxazide in the treatment of hepatic encephalopathy in Egyptian patients with liver cirrhosis https:\/\/clinicaltrials.gov\/study\/NCT05754996"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/liv.15510","article-title":"Diagnosis and management of hepatic encephalopathy: the French recommendations","volume":"43","author":"Thabut","year":"2023","journal-title":"Liver International"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/hepr.13678","article-title":"Evidence-based clinical practice guidelines for liver cirrhosis 2020","volume":"51","author":"Yoshiji","year":"2021","journal-title":"Hepatology Research"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.rgmxen.2023.04.006","article-title":"Current vision on diagnosis and comprehensive care in hepatic encephalopathy","volume":"88","author":"Higuera-de-la-Tijera","year":"2023","journal-title":"Revista de Gastroenterolog\u00eda de M\u00e9xico"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.dld.2018.11.035","article-title":"Hepatic encephalopathy 2018: a clinical practice guideline by the Italian Association for the Study of the Liver (AISF)","volume":"51","author":"Montagnese","year":"2019","journal-title":"Digestive and Liver Disease"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2","DOI":"10.54393\/pjhs.v5i05.1499","article-title":"Pakistan Society of Hepatology Guidelines on the management of hepatic encephalopathy","volume":"5","author":"Naeem","year":"2024","journal-title":"Pakistan Journal of Health Sciences"},{"issue":"36","key":"10.1002\/14651858.CD012734.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.3748\/wjg.v25.i36.5403","article-title":"Chinese guidelines on management of hepatic encephalopathy in cirrhosis","volume":"25","author":"Xu","year":"2019","journal-title":"World Journal of Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"e0650.19","DOI":"10.1097\/HC9.0000000000000650","article-title":"Safety and efficacy of a defined bacterial consortium, VE303, to treat HE","volume":"9","author":"Bloom","year":"2025","journal-title":"Hepatology Communications"},{"issue":"6","key":"10.1002\/14651858.CD012734.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003044.pub2","article-title":"Nonabsorbable disaccharides for hepatic encephalopathy","author":"Als-Nielsen","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7447","key":"10.1002\/14651858.CD012734.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/bmj.38048.506134.EE","article-title":"Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials","volume":"328","author":"Als Nielsen","year":"2004","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0105|cit105","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews. Cochrane: London, Version August 2023 community.cochrane.org\/sites\/default\/files\/uploads\/MECIR\/MECIR%20Version_August%202023_revised%20080424.pdf"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0106|cit106","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 [updated June 2017]. The Cochrane Collaboration, 2017 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0107|cit107","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0109|cit109","first-page":"n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0110|cit110","unstructured":"International Council for Harmonisation of technical requirements for pharmaceuticals for human use (ICH) ICH Harmonised Guideline. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2) database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0111|cit111","unstructured":"Cochrane Hepato-Biliary Group Information for authors hbg.cochrane.org\/information-authors"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0112|cit112","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies [last updated March 2025]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5.1 Cochrane, 2025 Available from cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0114|cit114","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.2.0"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"e076754","DOI":"10.1136\/bmj-2023-076754","article-title":"ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis","volume":"383","author":"Page","year":"2023","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0116|cit116","volume-title":"Statistical Power Analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0117|cit117","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Chapter 10: Analysing data and undertaking meta-analyses [last updated November 2024]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0118|cit118","unstructured":"Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1740774508091600","article-title":"Imputation methods for missing outcome data in meta-analysis of clinical trials","volume":"5","author":"Higgins","year":"2008","journal-title":"Clinical Trials"},{"issue":"7109","key":"10.1002\/14651858.CD012734.pub2-BIB0121|cit121","first-page":"629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"20","key":"10.1002\/14651858.CD012734.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0123|cit123","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0124|cit124","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0125|cit125","unstructured":"Thomas J Askie LM Berlin JA Elliott JH Ghersi D Simmonds M Chapter 22: Prospective approaches to accumulating evidence [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial Sequential Analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev","year":"2017","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0127|cit127","unstructured":"Thorlund K Engstr\u00f8m J Wetterslev J Brok J Imberger G Gluud C User Manual for Trial Sequential Analysis (TSA); 2nd edition. Copenhagen Trial Unit, 2017 Available from ctu.dk\/tsa\/learn-more"},{"issue":"7650","key":"10.1002\/14651858.CD012734.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0129|cit129","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0130|cit130","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2020"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/BF01072921","article-title":"Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial","volume":"23","author":"Atterbury","year":"1978","journal-title":"American Journal of Digestive Diseases"},{"issue":"5 II","key":"10.1002\/14651858.CD012734.pub2-BIB0132|cit132","first-page":"977","article-title":"Double -blind comparison of lactulose (L) and neomycin (N) plus sorbitol (S) in treatment of acute nitrogenous portalsystemic encephalopathy","volume":"70","author":"Atterbury","year":"1976","journal-title":"Gastroenterology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD012734.pub2-BIB0133|cit133","first-page":"46 PDIII\/8 1034","article-title":"Lactitol versus vancomycin in the treatment of acute hepatic encephalopathy: a double blind, randomized trial","volume":"34","author":"Blanc","year":"1993","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0134|cit134","first-page":"A79","article-title":"Lactitol vs vancomycin in the treatment of acute encephalopathy: a double blind study","volume":"17","author":"Blanc","year":"1993","journal-title":"Gastroenterologie Clinique et Biologique"},{"issue":"12","key":"10.1002\/14651858.CD012734.pub2-BIB0135|cit135","first-page":"1063","article-title":"Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial","volume":"18","author":"Blanc","year":"1994","journal-title":"Gastroent\u00e9rologie Clinique et Biologique"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012734.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/0168-8278(90)91368-7","article-title":"Treatment of acute hepatic encephalopathy (HE): lactulose-neomycin versus placebo. Randomized bioequivalence assay","volume":"11","author":"Blanc","year":"1990","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/0148607185009003288","article-title":"Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind, controlled trial","volume":"9","author":"Cerra","year":"1985","journal-title":"Journal of Parenteral and Enteral Nutrition"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0138|cit138","first-page":"699","article-title":"A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE)","volume":"2","author":"Cerra","year":"1982","journal-title":"Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD012734.pub2-BIB0139|cit139","first-page":"612","article-title":"Cirrhosis, encephalopathy, and improved results with metabolic support","volume":"94","author":"Cerra","year":"1983","journal-title":"Surgery"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0140|cit140","unstructured":"Cerra FB Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind, controlled trial [personal communication] Correspondence with authors"},{"issue":"4","key":"10.1002\/14651858.CD012734.pub2-BIB0141|cit141","first-page":"668","article-title":"Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report","volume":"36","author":"De Marco","year":"1984","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"7","key":"10.1002\/14651858.CD012734.pub2-BIB0142|cit142","first-page":"403","article-title":"Rifaximine versus neomycin in the treatment of portosystemic encephalopathy","volume":"23","author":"DiPiazza","year":"1991","journal-title":"Italian Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/S0011-393X(05)80681-2","article-title":"Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety","volume":"54","author":"Festi","year":"1993","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000198819","article-title":"A controlled clinical trial of nicotinohydroxamic acid and neomycin in advanced chronic liver disease","volume":"25","author":"Hirayama","year":"1982","journal-title":"Digestion"},{"issue":"10","key":"10.1002\/14651858.CD012734.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1185\/03007999709113333","article-title":"Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial","volume":"13","author":"Miglio","year":"1997","journal-title":"Current Medical Research and Opinion"},{"issue":"6","key":"10.1002\/14651858.CD012734.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/bf01308097","article-title":"Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study","volume":"26","author":"Orlandi","year":"1981","journal-title":"Digestive Diseases and Sciences"},{"issue":"5 II","key":"10.1002\/14651858.CD012734.pub2-BIB0147|cit147","first-page":"1042","article-title":"Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy. A randomized clinical study","volume":"79","author":"Orlandi","year":"1980","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0011-393X(05)80433-3","article-title":"Effect of rifaximin and paromycin in the treatment of portal-systemic encephalopathy","volume":"52","author":"Parini","year":"1992","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"4","key":"10.1002\/14651858.CD012734.pub2-BIB0149|cit149","first-page":"175","article-title":"Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial","volume":"23","author":"Pedretti","year":"1991","journal-title":"Italian Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0150|cit150","first-page":"133","article-title":"Ribostamycin for the treatment of hepatic encephalopathy: a crossover study with lactulose","volume":"45","author":"Russo","year":"1989","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0151|cit151","first-page":"18","article-title":"Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin","volume":"6","author":"Strauss","year":"1986","journal-title":"Nutritional Support Services"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0152|cit152","first-page":"862","article-title":"A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched-chain amino-acid solution compared to neomycin in hepatic encephalopathy","volume":"3","author":"Strauss","year":"1983","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012734.pub2-BIB0153|cit153","first-page":"542","article-title":"Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy","volume":"39","author":"Strauss","year":"1992","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0154|cit154","first-page":"1449","article-title":"Treatment of hepatic encephalopathy grades I or II: double blind randomized clinical trial comparing neomycin to placebo","volume":"8","author":"Strauss","year":"1988","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012734.pub2-BIB0155|cit155","first-page":"S183","article-title":"Treatment of hepatic encephalopathy grades I or II: double blind randomized clinical trial comparing neomycin to placebo","volume":"7","author":"Strauss","year":"1988","journal-title":"Journal of Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD012734.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/gut.31.6.702","article-title":"Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy","volume":"31","author":"Tarao","year":"1990","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD012734.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"283","DOI":"10.11150\/kansenshogakuzasshi1970.60.283","article-title":"Therapeutic effect of vancomycin hydrochloride, a nonabsorbable antibiotic, on intractable (lactulose resistant) chronic hepatic encephalopathy in cirrhotic patients","volume":"60","author":"Tarao","year":"1986","journal-title":"Kansenshogaku Zasshi"},{"issue":"6","key":"10.1002\/14651858.CD012734.pub2-BIB0158|cit158","first-page":"387","article-title":"A non-absorbable rifamycin for treatment of hepatic encephalopathy","volume":"11","author":"Testa","year":"1985","journal-title":"Drugs under Experimental and Clinical Research"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0016-5085(81)90658-2","article-title":"Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double-blind randomized controlled study","volume":"81","author":"Uribe","year":"1981","journal-title":"Gastroenterology"},{"issue":"5 II","key":"10.1002\/14651858.CD012734.pub2-BIB0160|cit160","first-page":"1061","article-title":"Successful use of lactose enemas in acute portal systemic encephalopathy (PSE). A double blind controlled trial","volume":"79","author":"Uribe","year":"1980","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012734.pub2-BIB0161|cit161","first-page":"420","article-title":"Comparison of the administration of lactulose and metronidazol vs lactulose or metronidazol in the treatment of acute","volume":"32","author":"Ram\u00edrez-Palma","year":"2016","journal-title":"Medicina Interna de Mexico"},{"issue":"8","key":"10.1002\/14651858.CD012734.pub2-BIB0162|cit162","first-page":"1367","article-title":"Effect of treatment with paromomycin on endotoxemia in patients with alcoholic liver disease--a double-blind, placebo-controlled trial","volume":"21","author":"Bode","year":"1997","journal-title":"Alcoholism: Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0163|cit163","first-page":"625","article-title":"Metranidazole in hepatic encephalopathy","volume":"42","author":"Held","year":"1987","journal-title":"Zeitschrift f\u00fcr Klinische Medizin"},{"issue":"Suppl XIII","key":"10.1002\/14651858.CD012734.pub2-BIB0164|cit164","first-page":"63","article-title":"Metronidazole for hepatic encephalopathy","volume":"66","author":"Held","year":"1988","journal-title":"Wiener Klinische Wochenschrift"},{"issue":"2","key":"10.1002\/14651858.CD012734.pub2-BIB0165|cit165","first-page":"63","article-title":"Changes in the levels of ammonia and free phenols in patients with portacaval shunt treated with lactulose and\/or neomycin compared to a low protein diet (author's translation)","volume":"73","author":"Leonhardt","year":"1978","journal-title":"Medizinische Klinik"},{"issue":"32","key":"10.1002\/14651858.CD012734.pub2-BIB0166|cit166","first-page":"473","article-title":"Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial","volume":"47","author":"Tromm","year":"2000","journal-title":"Hepatogastroenterology"},{"issue":"Suppl","key":"10.1002\/14651858.CD012734.pub2-BIB0167|cit167","first-page":"198","article-title":"Efficacy of the orthograde intestinal enemas with mannit-solutions versus paromomycin+lactulose after upper gastrointestinal bleed in liver cirrhosis","volume":"107","author":"Tromm","year":"1995","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0168|cit168","first-page":"S51","article-title":"Efficacy of orthrograde whole gut irrigation with mannite vs paromomycin + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding","volume":"27","author":"Tromm","year":"1995","journal-title":"Endoscopy"},{"issue":"12","key":"10.1002\/14651858.CD012734.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/BF01308043","article-title":"Treatment of chronic portal-systemic encephalopathy with lactose in lactase-deficient patients","volume":"25","author":"Uribe","year":"1980","journal-title":"Digestive Diseases and Sciences"},{"issue":"Suppl","key":"10.1002\/14651858.CD012734.pub2-BIB0170|cit170","first-page":"120","article-title":"Vegetable protein diets with or without non-absorbable antibiotics for the treatment of chronic portal systemic encephalopathy","volume":"42","author":"Uribe","year":"1990","journal-title":"Revista de Investigaci\u00f3n Cl\u00ednica"},{"issue":"3","key":"10.1002\/14651858.CD012734.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/00004836-198206000-00013","article-title":"Effect of paromomycin sulfate on endotoxemia in patients with cirrhosis","volume":"4","author":"Tarao","year":"1982","journal-title":"Journal of Clinical Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD012734.pub2-BIB0172|cit172","first-page":"349","article-title":"Effect of long-term administration of paromomycin sulfate on the level of serum albumin and gamma-globulin in human cirrhosis","volume":"8","author":"Tarao","year":"1983","journal-title":"Tokai Journal of Experimental and Clinical Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012734.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2957\/kanzo.22.710","article-title":"Effect of long-term non-absorbable antibiotics administration on the cirrhotic process: i. Effect of paromomycin sulfate administration on the level of serum albumin and gamma-globulin in cirrhosis in man","volume":"22","author":"Tarao","year":"1981","journal-title":"Acta Hepatologica Japonica"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0174|cit174","unstructured":"Chesta J Antezana C Effects of neomycin on intestinal digestion, absorption and fermentation of carbohydrates in patients with liver cirrhosis: evidence for an alternative therapeutic mechanism in hepatic encephalopathy Revista Medica de Chile 1994 122 4 365 71 7809530"},{"issue":"1","key":"10.1002\/14651858.CD012734.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/gut.23.1.1","article-title":"Treatment of hepatic encephalopathy with metronidazole","volume":"23","author":"Morgan","year":"1982","journal-title":"Gut"},{"key":"10.1002\/14651858.CD012734.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.14309\/00000434-200809001-00392","article-title":"A pilot study utilizing nitazoxanide for hepatic encephalopathy in chronic liver failure","volume":"103","author":"Basu","year":"2008","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD012734.pub2-BIB0177|cit177","first-page":"A49","article-title":"A pilot utilizing nitazoxanide for hepatic encephalopathy in chronic liver failure","volume":"23","author":"Basu","year":"2008","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD012734.pub2-BIB0178|cit178","first-page":"1085A","article-title":"A pilot study utilizing nitazoxanide for hepatic encephalopathy in chronic liver failure","volume":"48","author":"Basu","year":"2008","journal-title":"Hepatology"},{"issue":"7572","key":"10.1002\/14651858.CD012734.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"804-6","DOI":"10.1136\/bmj.38987.492014.94","article-title":"How to formulate research recommendations","volume":"333","author":"Brown","year":"2006","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"7","key":"10.1002\/14651858.CD012734.pub2-BIB0180|cit180","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012734","article-title":"Aminoglycosides and metronidazole for people with cirrhosis and hepatic encephalopathy","author":"Jeyaraj","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012734.pub2-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1086\/647939","article-title":"Metronidazole is still the drug of choice for treatment of anaerobic infections","volume":"50","author":"L\u00f6fmark","year":"2010","journal-title":"Clinical Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD012734.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/BF01967563","article-title":"Structure, biochemistry and mechanism of action of glycopeptide antibiotics","volume":"8","author":"Reynolds","year":"1989","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD012734.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.1840010414","article-title":"Mechanism of hepatic coma","volume":"1","author":"Zieve","year":"1981","journal-title":"Hepatology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:17:54Z","timestamp":1789096674000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012734.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":183,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012734.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}